Press release
United States Narcolepsy Therapeutics Market (2025) | Market Report include - Narcolepsy Drug, Narcolepsy Type 1, Central Nervous System Stimulants, Orexin Receptor Agonists, Sleep Disorder Treatment
Narcolepsy Therapeutics Maket Size 2025
narcolepsy therapeutics market reached US$ 2.93 billion in 2023, with a rise to US$ 3.19 billion in 2024, and is expected to reach US$ 6.98 billion by 2033, growing at a CAGR of 9.1% during the forecast period 2025-2033.
Connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/narcolepsy-therapeutics-market?kb
United States: Recent Industry Developments
✅ March 2026: Jazz Pharmaceuticals plc expanded commercialization initiatives for narcolepsy therapies focused on excessive daytime sleepiness and cataplexy management.
✅ February 2026: Harmony Biosciences Holdings, Inc. strengthened research activities for next-generation wake-promoting therapies targeting improved long-term patient outcomes.
✅ January 2026: Axsome Therapeutics, Inc. advanced clinical development programs for novel CNS therapies with potential applications in sleep-wake disorders including narcolepsy.
✅ December 2025: Avadel Pharmaceuticals plc increased focus on extended-release nighttime treatment formulations designed to improve sleep continuity in narcolepsy patients.
Download Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/narcolepsy-therapeutics-market?kb
List of Key Players 2026:
Jazz Pharmaceuticals, Inc., Avadel, Apotex Inc., Novartis AG, and Harmony Biosciences
Key Strategic Growth Forecast Projections 2026:
The Global Narcolepsy Therapeutics Market is entering a high-growth phase, with strong momentum expected throughout 2026-2033. Backed by accelerating industry adoption, strategic investments, and continuous innovation from leading players, the market is poised for significant expansion beyond its steady 2025 growth trajectory. The latest outlook highlights emerging opportunities, evolving competitive dynamics, and long-term revenue potential shaping the future of the industry.
Key Strategic Developments 2025-2026:
✅ May 2026: Eli Lilly announced plans to acquire Centessa Pharmaceuticals to strengthen its neuroscience and sleep disorder portfolio, expanding development of orexin receptor 2 agonists for narcolepsy and excessive daytime sleepiness.
✅ February 2026: Harmony Biosciences reported strong commercial growth for WAKIX®, with 2026 revenue guidance projected to exceed USD 1 billion, while advancing next-generation pitolisant formulations and orexin-2 agonist programs.
✅ January 2026: Axsome Therapeutics advanced AXS-12 toward regulatory submission for narcolepsy treatment following positive FDA pre-NDA feedback, strengthening its late-stage CNS therapeutics pipeline.
✅ January 2026: Harmony Biosciences continued expansion of its narcolepsy franchise through ongoing Phase 3 programs and development of next-generation formulations designed to extend long-term market exclusivity.
✅ November 2025: Centessa Pharmaceuticals reported positive Phase 2a data for ORX750, demonstrating strong wakefulness improvements in narcolepsy type 1 and type 2 patients, supporting advancement toward registrational studies.
✅ October 2025: Alkermes strengthened its position in sleep medicine through the acquisition of Avadel Pharmaceuticals, expanding its narcolepsy portfolio with Lumryz® for cataplexy and excessive daytime sleepiness treatment.
How Our Market Research Process Works:
The global Narcolepsy Therapeutics Market research report delivers strategic intelligence built through a robust blend of primary insights and extensive secondary research. The study provides a deep analysis of critical market forces shaping the industry, including regulatory developments, competitive positioning, evolving demand patterns, and historical market performance. It further highlights breakthrough technologies, innovation trends, and advancements across connected industries influencing the future of Narcolepsy Therapeutics adoption. The report also uncovers high-growth opportunities, investment potential, market risks, and key operational challenges, enabling businesses to make faster, data-driven decisions in an increasingly competitive landscape.
Funding/M&A/partnerships 2025-2026:
• May 2026: Angelini Pharma agreed to acquire Catalyst Pharmaceuticals for US$4.1 billion, strengthening its neuroscience and rare neurological disorders portfolio, including sleep-related therapies.
• March 2026: Eli Lilly and Company announced the acquisition of Centessa Pharmaceuticals for up to US$7.8 billion to expand its narcolepsy and sleep-wake disorder pipeline with orexin-targeting therapies.
• February 2026: Alkermes plc completed the acquisition of Avadel Pharmaceuticals, adding narcolepsy treatment LUMRYZ® and expanding its sleep medicine business.
• October 2025: Alkermes plc announced a US$2.1 billion deal to acquire Avadel Pharmaceuticals to strengthen its narcolepsy therapeutics portfolio and enter the sleep medicine market.
Request Strategic Market Customization: https://datamintelligence.com/customize/narcolepsy-therapeutics-market?kb
Japan: Recent Industry Developments
✅ March 2026: Takeda Pharmaceutical Company Limited enhanced neuroscience research collaborations targeting innovative therapies for rare neurological and sleep disorders.
✅ February 2026: Astellas Pharma Inc. expanded CNS therapeutic research programs focused on improving patient quality of life in sleep-related disorders.
✅ January 2026: Eisai Co., Ltd. strengthened development efforts for neurological disorder therapeutics leveraging advanced neuropharmacology platforms.
✅ December 2025: Sumitomo Pharma Co., Ltd. accelerated partnerships in CNS drug innovation to support next-generation narcolepsy and sleep disorder treatment development.
Major Segments Opportunity 2026:
By Disease Type: Narcolepsy Type 1, Narcolepsy Type 2
By Therapeutic Type: Central Nervous System Stimulants, Central Nervous System Depressants, Others
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies
Regional Growth Intelligence for Market:
⇥ North America: 42.1% - Leads the narcolepsy therapeutics market due to advanced healthcare infrastructure, strong diagnosis rates, and increasing adoption of novel sleep disorder treatments.
⇥ Europe: 24.3% - Growth supported by rising awareness of sleep disorders, favorable reimbursement policies, and expanding neurological treatment access.
⇥ Asia-Pacific: 19.5% - Fastest-growing regional market driven by improving healthcare access, growing patient population, and increasing investments in sleep medicine.
⇥ Latin America: 7.1% - Market expansion fueled by improving healthcare facilities and increasing awareness of narcolepsy diagnosis and treatment.
⇥ Middle East & Africa: 7.0% - Emerging demand supported by healthcare modernization initiatives and rising focus on neurological disorder management.
Unlock & Get Full 360° Best Strategic Report: https://www.datamintelligence.com/buy-now-page?report=narcolepsy-therapeutics-market?kb
Market Drivers 2026:
Rapid advancements in orexin receptor agonists and next-generation wakefulness-promoting therapies improving treatment efficacy and patient compliance.
Increasing development of non-stimulant therapies and extended-release formulations expanding treatment options for narcolepsy management.
Growing integration of digital sleep monitoring technologies and AI-based diagnostic tools enhancing early detection and personalized treatment approaches.
Expansion of clinical research activities focused on rare neurological disorders creating new growth opportunities in the Narcolepsy Therapeutics market.
Rising strategic collaborations among pharmaceutical companies, research institutes, and sleep disorder centers strengthening drug development pipelines.
Continuous innovation in CNS-targeted therapeutics and precision medicine approaches improving safety profiles and therapeutic outcomes.
Increasing focus on awareness campaigns, patient advocacy programs, and sleep health education accelerating diagnosis and treatment adoption worldwide.
Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Narcolepsy Therapeutics Market (2025) | Market Report include - Narcolepsy Drug, Narcolepsy Type 1, Central Nervous System Stimulants, Orexin Receptor Agonists, Sleep Disorder Treatment here
News-ID: 4511756 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Krabbe Disease Treatment Market to Reach USD 786.45 Million by 2033 at 16.8% CAG …
The global Krabbe disease treatment market was valued at approximately USD 262.25 million in 2025 and is projected to reach nearly USD 786.45 million by 2033, growing at a CAGR of 16.8% from 2026 to 2033. The market is witnessing rapid growth driven by increasing focus on rare genetic neurological disorders, rising investments in gene therapy development, and growing advancements in precision medicine for lysosomal storage diseases. Krabbe disease is…
Japan Sake Market (2026): Premiumization Trends Across Asia, Africa, and Latin A …
Market Growth & Size 2026-2033
Japan Sake Market reached US$ 1.36 billion in 2025 and is expected to reach US$ 1.89 billion by 2033, growing with a CAGR of 4.1% during the forecast period 2026-2033.
Connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/japan-sake-market?kb
Japan: Recent Industry Developments
✅ March 2026: Asahi Shuzo Co., Ltd. expanded global production capacity for Dassai premium sake to support growing international exports and luxury beverage…
Quantum Computing in Financial Services Market Set to Record US$ 9.3 Billion by …
DataM Intelligence has unveiled its latest research study, "Quantum Computing in Financial Services Market Size 2026," delivering strategic intelligence designed to identify high-growth opportunities, evaluate competitive positioning, and stay ahead of rapidly evolving market trends. The report provides a comprehensive analysis of market size, revenue performance, CAGR projections, regional growth patterns, and detailed segmentation insights, along with an in-depth assessment of the key factors driving industry expansion. It also highlights…
Drug Resistant Epilepsy Market to Reach US$ 1.28 Billion by 2033 at 4.4% CAGR; N …
The global drug resistant epilepsy market reached US$ 0.89 billion in 2025 and is expected to reach US$ 1.28 billion by 2033, growing at a CAGR of 4.4% during the forecast period from 2026 to 2033. The market is witnessing steady growth driven by the increasing prevalence of refractory epilepsy, rising demand for advanced neurology treatments, and growing adoption of targeted therapies and neurostimulation devices for seizure management. Expanding utilization…
More Releases for Pharma
Schizophrenia Market: Expanding Revenue Landscape to 2034 - DelveInsight | Teva …
The Key Schizophrenia Companies in the market inlclude - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, and others.
DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoring…
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Global Roxatidine Market overview:
Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the…
